PROQR THERAPEUTICS N.V.

 

Zernikedreef 9

2333 CK Leiden

The Netherlands

 

VIA EDGAR AND FEDERAL EXPRESS

 

March 7, 2022

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Michael Davis

 

Re:	ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333- 263166

 

Dear Mr. Davis:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 9, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

 

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling James Xu at (650) 752-3355. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: James Xu, by email to JXu@goodwinlaw.com.

 

If you have any questions regarding this request, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.

 

[Signature Page Follows]

 

 

	Sincerely,
	pROQR thERAPEUTICS N.V.
	/s/ Daniel de Boer
	Daniel de Boer
	Chief Executive Officer

  

cc:	Smital Shah, ProQR Therapeutics N.V.
	Mitchell S. Bloom, Goodwin Procter LLP
	Danielle M. Lauzon, Goodwin Procter LLP
	James Xu, Goodwin Procter LLP

 

[Signature Page to Acceleration Request]